J.W. Cole Advisors Inc. Sells 5,255 Shares of Johnson & Johnson (NYSE:JNJ)

J.W. Cole Advisors Inc. cut its stake in Johnson & Johnson (NYSE:JNJFree Report) by 8.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,359 shares of the company’s stock after selling 5,255 shares during the period. J.W. Cole Advisors Inc.’s holdings in Johnson & Johnson were worth $9,071,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Granite Harbor Advisors Inc. lifted its position in shares of Johnson & Johnson by 6.0% during the first quarter. Granite Harbor Advisors Inc. now owns 7,263 shares of the company’s stock valued at $1,149,000 after buying an additional 413 shares during the last quarter. Retirement Systems of Alabama lifted its position in shares of Johnson & Johnson by 30.2% during the first quarter. Retirement Systems of Alabama now owns 1,234,969 shares of the company’s stock valued at $195,360,000 after buying an additional 286,528 shares during the last quarter. Hartline Investment Corp purchased a new stake in shares of Johnson & Johnson during the first quarter valued at about $3,597,000. North Star Investment Management Corp. lifted its position in shares of Johnson & Johnson by 0.5% during the first quarter. North Star Investment Management Corp. now owns 65,255 shares of the company’s stock valued at $10,323,000 after buying an additional 319 shares during the last quarter. Finally, Mcintyre Freedman & Flynn Investment Advisers Inc. increased its holdings in shares of Johnson & Johnson by 9.1% during the first quarter. Mcintyre Freedman & Flynn Investment Advisers Inc. now owns 12,192 shares of the company’s stock valued at $1,929,000 after acquiring an additional 1,020 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a report on Monday, June 17th. The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, July 1st. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price objective for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, Morgan Stanley cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $174.07.

View Our Latest Research Report on JNJ

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $146.48 on Friday. The stock has a market capitalization of $352.53 billion, a price-to-earnings ratio of 9.13, a PEG ratio of 2.42 and a beta of 0.52. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The firm’s 50 day simple moving average is $147.94 and its 200-day simple moving average is $153.73. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter last year, the company earned $2.68 EPS. The business’s revenue was up 2.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.62 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.